Categories AlphaGraphs, Earnings, Health Care
Earnings: Pfizer edges past Q4 estimates, shares dip on weak outlook
Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share from 62 cents per share a year ago, surpassing analysts’ estimate of 63 cents per share.
During the quarter, an 8% growth in Innovative Health top-line was partly offset by a 7% decline in its smaller Essential Health segment.
PFE shares were down 3% during pre-market trading on Tuesday as investors were not impressed by the outlook given by the company.
Pfizer said it expects revenues to come in the range of $52 billion to $54 billion for the full year 2019, while adjusted EPS is expected to come in the range of $2.82 to $2.92.
Shares of the pharmaceutical giant have been almost flat in the last 12 months. It closed its last trading session down 2.73% on Monday.
Pfizer Q4 2018 complete earnings call transcript
Albert Bourla, who took charge as the CEO on Jan 1, said, “2019 is expected to be a busy year with important clinical data readouts across our early-, mid- and late-stage pipeline. In the near term, we expect to report pivotal top-line results for tanezumab in chronic lower back pain as well as additional data in osteoarthritis following today’s announcement of a second positive Phase 3 trial.”
Last week, Pfizer was downgraded from Buy to Neutral by UBS analyst Navin Jacob who raised concerns about the company’s patent cliffs for many of its key products. In November, Pfizer lost a patent war in the UK for its drug Lyrica.
The biggest development during the quarter was the joint venture between Pfizer and GlaxoSmithKline plc (GSK) on their consumer health businesses. The transaction is expected to close in the second half of this year and the combined entity will be a giant in the consumer health sector. This will be a key point to watch out for during the results announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on